Literature DB >> 3093750

[Clinical evaluation of N-acetylaspartylglutamic acid eyedrops in subacute and chronic atopic conjunctivitis].

O P van Bijsterveld, V Aalders-Deenstra.   

Abstract

Patients with subacute and chronic atopic conjunctivitis who were treated for at least one year with topically applied 2% sodium cromoglycate 4 times daily were switched to N.A.A.G.A. 6% eye drops for 2 months. A statistically significant gain in treatment effect as assessed objectively (+12.25%) and subjectively (+25.90%) was obtained. This effect could be the result of a more effective antiallergic action of N.A.A.G.A. or could be related to a relative tachyphylaxis to sodium cromoglycate.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3093750     DOI: 10.1055/s-2008-1050733

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  5 in total

Review 1.  Ocular allergy treatments.

Authors:  L Bielory
Journal:  Clin Rev Allergy Immunol       Date:  2001-04       Impact factor: 8.667

Review 2.  Drug treatment of allergic conjunctivitis. A review of the evidence.

Authors:  G Ciprandi; S Buscaglia; P M Cerqueti; G W Canonica
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

3.  Treatment of common ocular allergic disorders; a comparison of lodoxamide and NAAGA.

Authors:  D Denis; E Bloch-Michel; P Verin; A Sebastiani; M Tazartes; L Helleboid; A Di Giovanni; M Lecorvec
Journal:  Br J Ophthalmol       Date:  1998-10       Impact factor: 4.638

4.  N-acetyl-aspartyl glutamic acid (NAAGA) topical eyedrops in the treatment of giant papillary conjunctivitis (GPC).

Authors:  F Meijer; K Pogany; J H Kok; A Kijlstra
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

5.  Clinical and biological efficacy of preservative-free NAAGA eye-drops versus levocabastine eye-drops in vernal keratoconjunctivitis patients.

Authors:  A Leonardi; D Bremond-Gignac; M Bortolotti; D Violato; P Pouliquen; L Delval; J M Grouin; I A Fregona
Journal:  Br J Ophthalmol       Date:  2007-06-21       Impact factor: 4.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.